-
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
•
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has obtained its 10th indication approval from China’s National Medical Products Administration (NMPA). The drug can now be used to treat early high-risk triple negative breast cancer (TNBC) with tumors expressing PD-L1 (CPS ≥ 20) in…
-
Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China
•
The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit announce a partnership with the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE). The collaboration aims to enhance professional collaborations in the rare disease field. Financial details of the…
-
Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies
•
Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings,…
-
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
•
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The company reported a 16% year-on-year (YOY) growth in constant exchange rates (CER) to DKK 128.9 billion (USD 17.3 billion) over the 9-month period. Sales for the three-month Q3 period were up 15% (CER) to DKK…
-
Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE
•
Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) unveiled at the 5th China International Import Expo (CIIE). The Denmark-based major will be provided with smart and modern logistics warehouses, enabling intensive, standardized, information-based, and intelligent drug logistics management and operation for…
-
SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round
•
China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million) in a Series C1 financing round, alongside “tens of millions” in bank loans. Investors included Guanzi Private Fund Management, Tian Rui Feng Nian, and Yixing Huarui. The proceeds will be used to support pre-clinical development,…
-
PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
•
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, announce partnerships with Swiss giant Roche and its compatriot firm OrigiMed, a precision medicine company. The collaboration aims to expand the pan-solid tumor payment service mode,…
-
Organon Partners with Alibaba Health to Enhance Chronic Disease Management
•
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, has announced another strategic deal at the 5th China International Import Expo (CIIE). This time, Organon is partnering with Alibaba Health Information Technology Ltd…
